Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company, has announced its participation in the Bank of America CNS Therapeutics Virtual Conference. The company, which is developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, will engage in a fireside chat on Monday, Oct. 7, 2024, at 8:00 a.m. ET.
Interested parties can access the live webcast of the event through the Investors tab on www.acumenpharm.com. The webcast will remain archived on the site for 90 days following the conference, allowing those unable to attend the live session to review the discussion at their convenience.
Acumen Pharmaceuticals (NASDAQ: ABOS), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione alla Conferenza Virtuale sulla Terapia CNS di Bank of America. L'azienda, che sta sviluppando una nuova terapia mirata ai tossici oligomeri solubili dell'amiloide beta per il trattamento dell'Alzheimer, parteciperà a una chiacchierata informale lunedì 7 ottobre 2024, alle 8:00 ET.
Le parti interessate possono accedere alla diretta webcast dell'evento attraverso la sezione Investitori su www.acumenpharm.com. La diretta rimarrà archiviata sul sito per 90 giorni dopo la conferenza, permettendo a chi non può partecipare alla sessione dal vivo di rivedere la discussione comodamente.
Acumen Pharmaceuticals (NASDAQ: ABOS), una compañía biofarmacéutica en etapa clínica, ha anunciado su participación en la Conferencia Virtual de Terapias CNS de Bank of America. La compañía, que está desarrollando una nueva terapia dirigida a los oligómeros de amiloide beta solubles tóxicos para el tratamiento de la enfermedad de Alzheimer, participará en una charla informal el lunes 7 de octubre de 2024, a las 8:00 a.m. ET.
Las partes interesadas pueden acceder a la transmisión en vivo del evento a través de la pestaña de Inversores en www.acumenpharm.com. La transmisión se mantendrá archivada en el sitio durante 90 días después de la conferencia, lo que permitirá a quienes no puedan asistir a la sesión en vivo revisar la discusión en su conveniencia.
Acumen Pharmaceuticals (NASDAQ: ABOS)는 임상 단계의 바이오 제약 회사로, Bank of America CNS 치료법 가상 회의에 참가한다고 발표했습니다. 이 회사는 알츠하이머병 치료를 위한 독성 용해성 아밀로이드 베타 올리고머를 표적으로 하는 새로운 치료제를 개발하고 있으며, 2024년 10월 7일 월요일 오전 8시(ET)에 간담회에 참여할 예정입니다.
관심 있는 당사자는 www.acumenpharm.com의 투자자 탭을 통해 행사 생중계를 시청할 수 있습니다. 생중계는 회의 후 90일 동안 사이트에 보관되어 있어, 실시간 세션에 참석할 수 없는 이들이 편리할 때 논의를 검토할 수 있습니다.
Acumen Pharmaceuticals (NASDAQ: ABOS), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à la Conférence Virtuelle sur les Thérapies CNS de Bank of America. L'entreprise, qui développe une nouvelle thérapie ciblant les oligomères beta-amyloïdes solubles toxiques pour le traitement de la maladie d'Alzheimer, participera à une discussion informelle le lundi 7 octobre 2024, à 8h00 ET.
Les parties intéressées peuvent accéder à la diffusion en direct de l'événement via l'onglet Investisseurs sur www.acumenpharm.com. La diffusion restera archivée sur le site pendant 90 jours après la conférence, permettant à ceux qui ne peuvent pas assister à la session en direct de revoir la discussion à leur convenance.
Acumen Pharmaceuticals (NASDAQ: ABOS), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, hat seine Teilnahme an der Bank of America CNS Therapeutics Virtuellen Konferenz bekannt gegeben. Das Unternehmen, das eine neuartige Therapie zur gezielten Bekämpfung von toxischen löslichen Amyloid-Beta-Oligomeren zur Behandlung von Alzheimer entwickelt, wird am Montag, den 7. Oktober 2024, um 8:00 Uhr ET an einem informellen Gespräch teilnehmen.
Interessierte Parteien können über den Investoren-Tab auf www.acumenpharm.com auf die Live-Webcast des Events zugreifen. Der Webcast bleibt für 90 Tage nach der Konferenz auf der Seite archiviert, sodass diejenigen, die an der Live-Sitzung nicht teilnehmen können, die Diskussion bequem nachholen können.
- None.
- None.
NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Bank of America CNS Therapeutics Virtual Conference on Monday, Oct. 7, 2024, at 8:00 a.m. ET.
The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When is Acumen Pharmaceuticals (ABOS) participating in the Bank of America CNS Therapeutics Virtual Conference?
What is the focus of Acumen Pharmaceuticals' (ABOS) drug development?
How can investors access Acumen Pharmaceuticals' (ABOS) fireside chat at the conference?
What type of company is Acumen Pharmaceuticals (ABOS)?
